Revenue segments as reported by the company.

Cardiovascular

Medical Surgical

Neuroscience

Diabetes

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Amortization of intangible assets

Restructuring charges, net

Certain litigation charges, net

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Medtronic

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Medtronic reports strong Q4 results, anticipates margin pressures for FY '24

MDT reported strong Q4 results with organic revenue growth, but anticipates margin pressures and EPS decline for FY '24. They highlighted successful FDA approvals and expressed confidence in growth opportunities.

Medtronic reports strong Q2 earnings, highlights growth opportunities

Medtronic's Q2 earnings call showcased strong financial performance, with raised full-year guidance. The company emphasized growth in key business segments and highlighted opportunities in insulin-dependent patient solutions and AI-powered solutions. Challenges include delays in PMRI spend and minimal impact of GLP-1s on the business.

Medtronic exceeds Q3 expectations, focuses on growth and transformation

Medtronic's Q3 earnings call highlighted strong performance, raised outlook, and a focus on transformation for sustainable growth. The company is strategically addressing challenges through cost reduction efforts and seizing opportunities in key markets. Medtronic remains committed to driving innovation and maximizing shareholder value.

Medtronic exceeds Q4 expectations, eyes growth in innovative healthcare

Medtronic's Q4 performance showcased strong growth in key segments, with a focus on innovation and market expansion. Despite challenges from inflation and currency impact, the company remains optimistic about future growth opportunities driven by product advancements and strategic acquisitions.

Medtronic reports robust Q1 results, eyes growth amid challenges

Medtronic's Q1 performance showcased strong revenue growth and emphasized innovation across key business segments.
While facing challenges of growth deceleration and margin expansion, the company remains focused on operational efficiencies and market fundamentals.
Opportunities lie in bariatric space growth, ongoing transformation efforts, and advancements in diabetes programs and surgical systems.
Overall, Medtronic's strategic investments in technology, pricing strategies, and procedural trends position it for continued success and market leadership.

Medtronic surpasses revenue expectations, eyes growth in key markets

Medtronic delivered strong Q2 results with revenue growth ahead of expectations and raised full-year guidance. Despite concerns about GLP-1 drugs and the SELECT trial, the company remains optimistic about growth prospects, focusing on key markets and product innovation.

Medtronic reports solid Q3 growth, focuses on innovation and profitability

Medtronic's Q3 earnings call showcased strong financial performance, international market growth, and strategic decisions to drive innovation and profitability. The company's focus on new technologies, portfolio management, and overcoming challenges highlights a path towards sustained growth and earnings leverage. With positive progress in key business segments and a commitment to future profitability, Medtronic is well-positioned for continued success.

Medtronic reports robust Q4 growth, eyes operational efficiency and China

Medtronic's Q4 2024 earnings call highlighted strong revenue growth, new product launches, and a focus on restoring earnings power. The company provided guidance for fiscal year '25, expecting organic revenue growth, operating margin expansion, and non-GAAP diluted EPS. Analyst questions centered on EPS guidance, revenue growth drivers, and operational efficiencies.

Medtronic reports solid Q1 results, raises guidance for fiscal '25

Medtronic's Q1 2025 performance reflects steady revenue growth and increased EPS, driven by strong performances in key business segments and global markets.
The company's focus on innovation, strategic partnerships, and diversified revenue streams positions it well for future growth and market expansion.
While challenges exist in maintaining growth momentum and navigating market complexities, Medtronic's raised guidance and growth expectations signal confidence in its ability to drive top-line growth and restore earnings power.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Chegg

Credit Suisse

Ford Motor Company

General Motors

L3Harris

Teladoc

Markets will exploit investors who are too patient and forgiving on companies that are the value traps. These companies mask as deeply discounted companies that appear to have plenty of margin of safety and low risk.

7 Value-Trap Stocks That Will Punish the Bagholders

American Electric Power Company

Amgen

Broadcom

Comcast

ConocoPhillips

Cisco Systems

Coca-Cola

Morgan Stanley

Pfizer

PNC Financial Services

Phillips 66

Sempra Energy

Truist Financial

U.S. Bancorp

Vanguard High Dividend Yield ETF

There are 17 stocks on my high-yield watchlist for March 2023. The majority of the stocks on my watchlist are undervalued based on dividend yield theory.

High Yield Stock Watchlist: March 2023

Medtronic plc (NYSE:MDT ) Cowen 43rd Annual Healthcare Conference March 6, 2023 10:30 AM ET Company Participants Karen Parkhill - Executive Vice President and Chief Financial Officer Conference Call Participants Josh Jennings - Cowen and Company Josh Jennings We are moving down the medical devices track here at the TD Cowen 43rd Annual Healthcare Conference. We're excited to have Karen Parkhill, the Chief Financial Officer, Executive Vice President at Medtronic, the largest medical device company in the world.

Medtronic plc (MDT) Cowen 43rd Annual Healthcare Conference (Transcript)

ACC.23/WCC late-breaking data: PULSED AF, one of the most rigorously executed PFA clinical studies to date, exceeds safety and efficacy performance goals in the treatment of paroxysmal and persistent atrial fibrillation DUBLIN and NEW ORLEANS , March 6, 2023 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that its PulseSelect™ Pulsed Field Ablation (PFA) System exceeded its safety performance goal, with an adverse event rate of 0.7%, one of the lowest adverse event rates of any prior U.S. FDA Investigational Device Exemption (IDE) trial for atrial fibrillation (AF) ablation or any multi-center PFA study. PULSED AF exceeded the threshold for its efficacy performance goal and further, clinical success, freedom from recurrence of any symptomatic atrial arrhythmias, was at least 80% for each patient cohort.

Medtronic PulseSelect PFA System demonstrates impressive results in landmark PULSED AF global IDE trial

GE HealthCare Technologies Inc

Microsoft

NVIDIA

Healthcare AI stocks are on the rise with the introduction of AI-based solutions. These solutions allow companies to improve operations and cut costs using artificial intelligence.

4 AI Stocks That Are Revolutionizing Healthcare

DUBLIN , March 2, 2023 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, March 2, 2023, approved the fiscal year 2023 fourth quarter cash dividend of $0.68 per ordinary share, representing an 8% increase over the prior year. This quarterly declaration is consistent with the dividend announcement made by the company in May 2022.

Medtronic Announces Cash Dividend for Fourth Quarter of Fiscal Year 2023

This medical technology-oriented business is a proven innovator.

Is This Dividend Growth Stock a Buy Right Now?

McDonald's

AT&T

These three stocks will give you some great diversification to go along with above-average payouts.

Want to Collect a Dividend Every Month? Invest in These 3 Stocks

Innovation and consistent dividend increases attract investors.

Is Medtronic Still a Great Dividend Stock?

AbbVie

Johnson & Johnson

With a little planning, you can receive a dependable dividend payout every month.

Get a Dividend Every Month With These 3 Healthcare Stocks

DUBLIN , Feb. 27, 2023 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced it will participate in the 43rd annual Cowen healthcare conference on Monday, March 6, 2023. Karen Parkhill, Medtronic executive vice president and chief financial officer, will answer questions on the company beginning at 10:30 a.m.

Medtronic Executive Vice President and CFO Karen Parkhill to speak at Cowen healthcare conference

Medtronic's (MDT) MiniMed 780G system was designed to forecast real-life requirements where carbohydrate counts aren't always exact and meal doses are often missed.

Medtronic's (MDT) MiniMed 780G System Shows Favorable Results

Abbott Labs

Exxon Mobil

Dividend Stocks To Buy Now? 3 For Your Watchlist

One of these top dividend stocks is a far more compelling buy today.

Better Dividend Stock: Abbott Laboratories or Medtronic?

Automatic Data Processing

Carlisle Companies

Lowe's

MGE Energy

RPM International

Sherwin-Williams

Telephone and Data Systems

Walgreens

But today, we are serving up the main course with these 11 stocks well on their way to becoming dividend kings. We have ordered this list by how many consecutive years these companies have grown their dividends.

These 11 stocks will be Dividend Kings in 5 years or less.

Clorox

Ecolab

Essex Property Trust

McCormick

Nordson

Realty Income Corp

J. M. Smucker

S&P Global

Stanley Black & Decker

Sysco

T. Rowe Price Group

V.F.

West Pharmaceutical Services

NOBL started the year off with a gain of 3.23% in January; it is thus far not faring as well in February, but the ETF is still positive year-to-date. I present 3 strategies that can theoretically beat the dividend aristocrat index in the long term.

My Best Dividend Aristocrats For March 2023

A second randomized controlled trial sponsored by JDRF also demonstrates superiority of automated insulin pump as first-in-line therapy for children with type 1 diabetes  DUBLIN and BERLIN , Feb. 24, 2023 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced one-year data from the ADAPT study (n=82), the first multi-national randomized controlled study comparing the performance of the MiniMed™ 780G advanced hybrid closed loop system1 (AHCL) against multiple daily injections (MDI) of insulin with an intermittently scanned CGM (isCGM). The study was done in adults (18 years of age and older) not meeting glycemic targets.

MiniMed™ 780G system demonstrates superiority over multiple daily injections with CGM for type 1 diabetes management at one-year in ADAPT study

Medtronic recently reported its Q3FY23 results, with revenue and earnings falling above our estimates.

Will Medtronic Stock See Higher Levels After An Upbeat Q3?

NEW YORK--(BUSINESS WIRE)--FGS Global, the strategic advisor for the global economy, today announced that Bill George, former Chairman and Chief Executive of Medtronic and currently an executive fellow at Harvard Business School, has become a senior advisor of the company. Mr. George, the author of "True North" and other best-selling books on business leadership, has served on the boards of Goldman Sachs, Exxon Mobil, Target, Novartis AG and Mayo Clinic.

Former Medtronic Chairman and Chief Executive Becomes Senior Advisor of FGS Global

Medtronic (MDT) Aurora EV-ICD system indicated for patients at risk of life-threatening arrhythmias.

Medtronic (MDT) Receives CE Mark Approval For Aurora System

Medtronic's (MDT) CGM business banks on strong sales of the MiniMed 780G system and the associated increase in CGM attachment rates on the strength of the Guardian 4 sensor in Q3.

Medtronic (MDT) Q3 Earnings Beat Estimates, Margins Down

News for Medtronic Stock (MDT)